|
Study
|
Myelotoxicity (%)
|
Nausea/vomiting (%)
|
Liver and renal injury (%)
|
Arrhythmia (%)
|
Fever (%)
|
|---|
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
Group 1
|
Group 2
|
|---|
|
Li G 2011 [17]
|
4 (13.3)
|
4 (13.3)
|
4 (13.3)
|
3 (10)
|
–
|
–
|
1 (3.3)
|
0 (0)
|
7 (23.3)
|
6 (20)
|
|
Yao Q 2012 [19]
|
12 (40)
|
10 (30)
|
5 (16.7)
|
5 (16.7)
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Zheng Q 2013 [20]
|
17 (28.3)
|
16 (26.6)
|
10 (16.7)
|
5 (8.3)
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Kang Y 2013 [21]
|
11 (24.4)
|
10 (22.2)
|
15 (25)
|
15 (25)
|
4 (8.8)
|
3 (6.6)
|
2 (3.3)
|
0 (0)
|
7 (15.5)
|
5 (11.1)
|
|
Wen J 2014 [22]
|
22 (73.3)
|
20 (66.6)
|
6 (20)
|
4 (13.3)
|
–
|
–
|
5 (16.6)
|
1 (3.3)
|
–
|
–
|
|
Yue G 2014 [23]
|
10 (23.3)
|
8 (18.6)
|
7 (16.3)
|
6 (14)
|
–
|
–
|
–
|
–
|
–
|
–
|
|
Tu J 2014 [24]
|
7 (15.5)
|
9 (20)
|
9 (20)
|
9 (20)
|
2 (4.4)
|
2 (4.4)
|
2 (4.4)
|
1 (2.2)
|
–
|
–
|
|
Xu J 2014 [25]
|
14 (40)
|
9 (25.7)
|
4 (11.4)
|
2 (5.7)
|
2 (5.7)
|
1 (2.8)
|
1 (2.8)
|
1 (2.8)
|
1 (2.8)
|
0 (0)
|
|
Hu X 2015 [27]
|
7 (16.3)
|
5 (12.2)
|
26 (60.4)
|
20 (48.7)
|
5 (11.6)
|
5 (12.1)
|
3 (6.9)
|
3 (7.3)
|
5 (11.6)
|
5 (12.1)
|
| |
P > 0.05
|
P > 0.05
|
P > 0.05
|
P > 0.05
|
P > 0.05
|
- Values are given as number of patients (%). Group 1 = Endostar combined with chemotherapeutic agents; Group 2 = chemotherapeutic agents alone
